Compare SCYX & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | VNRX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 35.0M |
| IPO Year | 2014 | 2012 |
| Metric | SCYX | VNRX |
|---|---|---|
| Price | $0.78 | $0.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $3.00 | $2.50 |
| AVG Volume (30 Days) | 366.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | $257,000.00 | ★ $1,233,511.00 |
| Revenue This Year | $170.77 | $60.84 |
| Revenue Next Year | $286.38 | $404.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.57 | $0.18 |
| 52 Week High | $1.29 | $0.94 |
| Indicator | SCYX | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 33.45 |
| Support Level | $0.75 | $0.19 |
| Resistance Level | $0.85 | $0.28 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 76.07 | 15.05 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.